Nonprofit

Title Due Date Maximum Award Amount Description
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344762
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344763
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Varies

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344760
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344761
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344764
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344754
U.S. Embassy Brussels PAS Annual Program Statement $100,000.00

The U.S. Embassy Brussels Public Affairs Section (PAS) of the U.S. Department of State is pleased to announce that funding is available through its Public Diplomacy Grants Program. This Annual Program Statement outlines our funding priorities, strategic themes, and the procedures for submitting requests for funding. Applications for programs are accepted on a rolling basis until the deadline. Each quarter prior to the deadline, a grant review committee reviews the applications. The deadline is necessary to provide sufficient time to process and award programs in advance of the end of our fiscal year on September 30, 2023. Purpose of Grants: PAS Brussels invites proposals for projects that strengthen ties between the United States and Belgium by highlighting shared values and promoting bilateral cooperation. Grant proposals must convey an American cultural element, support a priority program area (see below), or include a connection with American expert(s), organization(s), or institution(s) in a specific field that will promote increased understanding of U.S. policy and perspectives. Examples of PAS projects include, but are not limited to: Grassroots programs that address one of the priority program areas mentioned below, including; · Academic and professional lectures, seminars, and speaker programs; · Artistic and cultural workshops, joint performances, and exhibitions; · Youth leadership programs, especially for minority groups; · Professional and academic exchanges and projects; · Media co-ops and press outreach; · Entrepreneurship and innovation in technological or other fields; and · Sports-related programming. Priority Program Areas: · Programs that demonstrate active partnership between the United States and Belgium to address new and evolving security challenges, including disinformation; · Programs that counter the influences of radicalization and violent extremism, including political extremism; · Programs that highlight U.S.-Belgian cooperation that counters terrorism and transnational crime; · Programs that strengthen social cohesion, economic opportunity, and support for shared U.S. policy goals through promotion of diversity principles; · Programs that support a long-term investment in U.S.-Belgian ties through educational, cultural, professional, and other exchanges between our two countries; · Programs that have a national reach and impact by linking likeminded organizations across linguistic and regional divides; · Programs that highlight or foster U.S.-Belgian cooperation to address the climate crisis and/or energy security; and · Programs that allow engagement with youth audiences on the enduring relevance of our historical bonds. Participants and Audiences: · Youth, particularly those from underserved communities; · Women, particularly entrepreneurs and/or those from underserved communities · Underserved/Minority/Refugee communities · Cultural institutions; · Academic institutions; · Business leaders and entrepreneurs; · Community leaders; · U.S. and Belgian thought leaders; · Social and new media users; and · Journalists, media organizations. The following types of projects are not eligible for funding: · Projects relating to partisan political activity; · Charitable or development activities; · Construction projects; · Projects that support specific religious activities; · Fundraising campaigns; · Lobbying for specific legislation or projects; · Scientific research; or · Projects that duplicate existing projects. Authorizing legislation, type, and year of funding: Funding authority is Smith-Mundt FY2023 Public Diplomacy funds.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344752
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344753
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Varies

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344759
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Varies

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344756